Maxim Group Maintains Their Buy Rating on Moleculin Biotech (MBRX)


In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $3. The company’s shares opened today at $1.27.

McCarthy wrote:

“Moleculin Biotech announced that the first patients have been dosed in the company’s second clinical study evaluating Annamycin in adult patients with relapsed/refractory acute myeloid leukemia (AML).”

According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -4.9% and a 32.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inovio Pharmaceuticals, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moleculin Biotech with a $3 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.43 and a one-year low of $0.93. Currently, Moleculin Biotech has an average volume of 193.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia.